Queensland		(Affix identification label here)					
Government	URN:						
Respiratory Syncytial Virus	Family	name:					
(RSV) Nirsevimab	Given	name(s):					
Immunisation Consent	Addres	es:					
Facility:	Date o	f birth:		Sex:	M	□ F	
Interpreter Services							
Is an interpreter required? Yes No  If yes: the interpreter has provided a sight translation of the translated the informed consent form over the phore		ed consent form in perso	on				
Name of interpreter:	Code:		Langua	ige:			
Patient Details							
First name (if known):							
Note: Where the baby has not been named, use the term "Bab	y of" as	the first name. For multi	ple birth	ı, use <b>"Baby</b>	1 of", "	Baby 2 of	f".
Last name (for newborn infants, use mother's last name):							
Date of birth (DD/MM/YYYY):		Sex:	Inters	sex			
Medicare number (if known):							
Indigenous status:  Aboriginal Aboriginal & Torres Strait Islander Torres	Strait Is	lander Non-Indigen	ous	Not stated/	unknowr	า	
Parent or Legal Guardian Details							
Is the person who completed this consent form a:  Parent Legal guardian Other (specify):							
First name:		Last name:					
Telephone number (mobile preferred):		Email address:					
Mother's address (address on the mother's Medicare records)	:				Pos	stcode:	
Note: Mother's address is required to record newborn infant's in							
If this person is not a parent or legal guardian, but has parental is clinician is required to verify evidence such as decision-making a Informed Decision-making in Health Care – <a href="www.health.qld.gov.">www.health.qld.gov.</a>	authority	or court order and photo	D. Ref	er to the Que	ensland	d Health G	uide to
Documents verified:							
Verified by (print name):		Signature:					
Consent to Administer Nirsevimab							
I have read and understand the information contained in the RS carers information sheet regarding the potential benefits and ris			formatio	n for parents	and	Yes	s No
I have had an opportunity to have my questions answered.						Yes	s No
I understand immunisation details will be recorded by Queensland Register (AIR) and this information may be used by Queensland prevention, control and monitoring; or as otherwise authorised by	d Health	for recall, reminders, clin				Yes	s No
I consent for the administration of nirsevimab.						Yes	s No
Signature of parent/legal guardian/other person:				Date:			

Mother's address (address on the mother's Medicare records):	Postcode:			
Note: Mother's address is required to record newborn infant's immunisation in the Australian Immunisation Register.				
If this person is not a parent or legal guardian, but has parental rights and responsibilities to provide consent and comple clinician is required to verify evidence such as decision-making authority or court order and photo ID. Refer to the Queen Informed Decision-making in Health Care — <a href="https://www.health.qld.gov.au/consent/clinician-resources/guide-to-informed-decisio">www.health.qld.gov.au/consent/clinician-resources/guide-to-informed-decisio</a>	sland Health Guide to			
Documents verified:				
Verified by (print name): Signature:				
Consent to Administer Nirsevimab				
I have read and understand the information contained in the RSV Immunisation Nirsevimab – information for parents are carers information sheet regarding the potential benefits and risks of nirsevimab.	nd Yes No			
I have had an opportunity to have my questions answered.	Yes No			
I understand immunisation details will be recorded by Queensland Health and provided to the Australian Immunisation Register (AIR) and this information may be used by Queensland Health for recall, reminders, clinical follow-up; or diseas prevention, control and monitoring; or as otherwise authorised by or required by law.	Yes No			
I consent for the administration of nirsevimab.	Yes No			
Signature of parent/legal guardian/other person:  Date:				
	Scan the QR code for detailed eligibility			
This section does NOT replace the need for prescribing and documentation on a medical record.	criteria and clinical guidance.			
☐ Infant <5kg (<8 months of age) – 0.5mL (1 x 50mg prefilled syringe – IM injection) ☐ Infant ≥5kg (<8 months of age) – 1mL (2 x 50mg prefilled syringe – IM injection) ☐ Infant/child with certain complex medical conditions (8 to 19 months inclusive) This dose is not weight based – 2mL (2 x 100mg prefilled syringe – IM injection)				

Date nirsevimab administered: Clinician administering nirsevimab (print name): Designation: Signature: Name of hospital/clinic: Hospital/clinic phone number (landline preferred):